|
|
||||||||
RESEARCH REPORT |
1 Oral Biology and Pathology, School of Dentistry, University of Queensland, Brisbane 4072, Australia; and
2 Infectious Diseases Program, Science Research Centre, School of Life Sciences, Queensland University of Technology, Brisbane 4001, Australia
* corresponding author, p.ford{at}uq.edu.au
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: Porphyromonas gingivalis periodontal disease antibody response atherosclerosis mouse model
| INTRODUCTION |
|---|
|
|
|---|
Epidemiological studies have shown an increased risk of atherosclerotic disease with periodontal infection, although this association is not strong (Khader et al., 2004). An inherent problem with human studies is the presence of confounding variables, since periodontitis and cardiovascular disease share common risk factors, such as diet, lifestyle, infection history, and genetic background. Studies with apolipoprotein-E-deficient (apoE) mice have provided support for this association, demonstrating that inoculation with P. gingivalis resulted in enhanced atherosclerosis (Li et al., 2002; Lalla et al., 2003). Additionally, elevated antibody levels to P. gingivalis have been associated with coronary heart disease (Pussinen et al., 2003) and carotid artery stenosis (Taniguchi et al., 2003). In this light, the current study examined the humoral immune response to P. gingivalis in relation to atherosclerosis development in the apoE mouse model. P. gingivalis and C. pneumoniae infections, although located at different sites, contribute to the total pathogen burden. The atherogenic effect of the immune response to multiple pathogens has not previously been examined. The aim of the present study was to determine the effect of immunization with P. gingivalis and C. pneumoniae on antibody responses and the development of atherosclerosis in apoE/ mice.
| MATERIALS & METHODS |
|---|
|
|
|---|
Mice
This project was approved by the University of Queensland animal ethics review committee. Six-week-old male apoE (/) mice were obtained from the Animal Resources Centre (Canning Vale, Australia) and fed regular chow.
Immunization Procedure
Ten groups of mice (6/group) each received a different intraperitoneal immunization regime (Table
). Injections were weekly and consisted of viable P. gingivalis (108 organisms/100 µL/mouse) or C. pneumoniae (108 IFU/100 µL/mouse). As controls, groups of mice received injections of vehicle (sterile PBS or uninfected Hep2 cells diluted in SPG [100 µL/mouse], respectively). Mice were killed at 18 wks of age (after 11 injections) or at 34 wks of age (after 22 injections). Mice were anesthetized with ketamine (600 µg/mouse) and xylazine (3 mg/mouse) delivered intraperitoneally. Blood was collected from the left ventricle, then the heart was perfused with PBS. The contents of the chest cavity were removed and immersed in 2% neutral buffered formalin for 16 hrs at 4°C, then in 30% sucrose in PBS at 4°C for 2 days. The tissue was embedded in Tissue Tek® OCT (Optimal Cutting Temperature) embedding medium (Sakura Finetek U.S.A., Inc., Torrance, CA, USA), quenched, and stored in liquid nitrogen.
|
Serum Antibody Levels
Serum levels of anti-P. gingivalis, anti-C. pneumoniae, and anti-GroEL antibodies were measured by an ELISA technique (Gemmell et al., 2000, 2002a). Briefly, P. gingivalis ATCC 33277 (5 µg/mL), C. pneumoniae AO3 (5 µg/mL), or recombinant (r) GroEL (purified from Escherichia coli, Stressgen Biotechnologies Corporation, Victoria, Canada) (2 µg/mL) was coated onto 96-well plates (Maxisorb Immunoplates, Nunc, Roskilde, Denmark). Diluted serum samples were added, followed by peroxidase-conjugated sheep anti-mouse IgG (The Binding Site, Birmingham, UK). Substrate containing 0.0075% H2O2 and 2.5 mM Otolidine (Eastman Kodak, Rochester, NY, USA) was added, the reaction stopped after 10 min with 3 M HCl, and the optical density of the wells read at an absorbance of 450 and 655 nm. Antibody levels were determined from a standard curve of dilutions of normal mouse IgG (Caltag Laboratories, Burlingame, CA, USA) coated onto plates. Wells with PBS in place of serum samples were used to determine background values.
Identification of Infiltrating Cells
CD4+ and CD8+ T-cell subsets, Mac-3+ macrophages, and CD19+ B-cells were labeled according to an immunoperoxidase method. Following antigen retrieval (CD4, 1 mM EDTA, pH 89; CD8, CD19, 10 mM citrate buffer, pH 6 for 15 min, followed by heating at 8590 C for 15 min), sections were incubated with the following primary monoclonal antibodies: FITC-conjugated rat anti-mouse CD4 and CD8 and rat anti-mouse Mac-3 and CD19 (1:50) (Pharmingen, San Diego, CA, USA). This was followed by application of the Super PicTure Polymer Detection Kit (Zymed, Invitrogen, Carlsbad, CA, USA). Nuclei were counterstained with methyl green. Thymus within the sections was used as positive controls. PBS in place of the primary antibody acted as negative controls.
Identification of HSP60
HSP60 present in aortic sections was labeled by an avidin-biotin immunoperoxidase method (Gemmell et al., 2002b), with mouse anti-mammalian HSP60 (1:50) (LK-1 clone, Stressgen Biotechnologies Corp., Victoria, Canada). Sections were incubated with the primary antibody, biotinylated goat anti-mouse immunoglobulins (Zymed), and then streptavidin peroxidase (Zymed). The peroxidase was developed in a liquid DAB substrate-chromagen system (Zymed). Nuclei were counterstained with methyl green.
Statistical Analysis
Multivariate analysis of variance with the general linear model was used to test for differences in the lesion areas and serum antibody levels of the different groups. Pairs of groups were tested for significance by the Students t test. The association between levels of serum antibodies and lesion area was measured by the Pearson correlation coefficient, and the statistical significance of the correlation was determined from exact tables (Snedecor and Cochran, 1967). We used the Minitab statistical package (Minitab Inc., State College, PA, USA) to perform the analyses.
| RESULTS |
|---|
|
|
|---|
|
|
|
Production of anti-GroEL IgG antibodies was lower than for antibodies to the whole organisms. In general, higher levels of anti-GroEL antibodies were observed in mice immunized with P. gingivalis compared with C. pneumoniae. After 11 wks of immunizations, immunized mice demonstrated anti-GroEL antibody levels higher than those of control mice (p < 0.007), and for P. gingivalis-immunized mice, these levels were greater than for those immunized with C. pneumoniae (p < 0.049). After 22 injections of P. gingivalis, levels of anti-GroEL antibodies were increased compared with those in mice immunized 11 times (p < 0.001). This was not so for C. pneumoniae. Co-immunization inhibited levels of anti-GroEL antibodies compared with P. gingivalis alone, but only if P. gingivalis was given first (p < 0.044) (Fig. 3C
).
Association of Serum Antibody Levels and Lesion Size
The association of the antibody response of mice killed after 22 injections with lesion surface area was measured. This was found to be significant for mice immunized with P. gingivalis alone (Groups 2, 5, and 7 analyzed), but not for mice immunized with C. pneumoniae alone (Groups 3, 6, and 7 analyzed). For P. gingivalis-immunized groups, levels of anti-P. gingivalis antibodies as well as levels of anti-GroEL antibodies were correlated with lesion surface area (r = 0.96, p < 0.05; r = 0.97, p < 0.05, respectively).
Immunohistology
The atherosclerotic lesions were macrophage/foam-cell-dominated, with most lipid deposits being intracellular. There was an inflammatory cell infiltrate composed almost entirely of macrophages, with very few CD4-, CD8-, or CD19-positive cells observed (Fig. 1D
). HSP60 was expressed by endothelial cells and some inflammatory cells (Fig. 1E
). This was observed in both immunized and control mice.
| DISCUSSION |
|---|
|
|
|---|
The response of co-immunized mice was inhibited compared with that of mice immunized with P. gingivalis only. These mice also demonstrated reduced atherosclerotic lesion development, suggesting a role for the anti-P. gingivalis immune response in atherogenesis. Increased total burden of P. gingivalis, therefore, enhanced specific antibody production and atherosclerosis. When a C. pneumoniae immune response was superimposed on an existing P. gingivalis response, however, anti-P. gingivalis antibody production and atherosclerosis were inhibited. The antibody response has previously been shown to be modulated by co-immunization with P. gingivalis and F. nucleatum in mice (Gemmell et al., 2004). Exposure to P. gingivalis in the presence of an anti-C. pneumoniae response caused an inhibition of anti-C. pneumoniae antibody production, but this was not associated with reduced atherosclerosis. These results show that the immune response to multiple pathogens appears to be much more complex than simply the sum of the responses to the separate pathogens.
As expected, antibodies specific for a single antigen, GroEL, were produced at lower levels than those specific for the whole bacteria. After 11 injections, there was a significant anti-GroEL antibody response. An increasing pathogen burden of P. gingivalis, but not of C. pneumoniae, enhanced this response. Similarly to the anti-P. gingivalis antibody response, co-immunization with P. gingivalis given before C. pneumoniae inhibited anti-GroEL antibodies compared with P. gingivalis alone, and this group also exhibited reduced atherosclerotic lesion development. Overall, the anti-GroEL antibody response was stronger in P. gingivalis- than in C. pneumoniae-immunized mice, suggesting that GroEL may be more important in the humoral response to P. gingivalis than to C. pneumoniae.
The results of the present study show that increasing the total burden of the periodontopathogen P. gingivalis caused enhanced atherosclerosis, and that the addition of another pathogen, C. pneumoniae, altered the immune response and net atherosclerotic effect. Further, the increased production of anti-GroEL antibodies with increasing P. gingivalis burden was associated with atherosclerosis severity. These results, along with the expression of hHSP60 by cells of the lesion, support the hypothesis of molecular mimicry as a mechanism involved. Interestingly, the antibody response elicited by P. gingivalis, but not by C. pneumoniae, was correlated with atherosclerosis progression. It is possible that molecular mimicry involving C. pneumoniae GroEL occurs; however, as an obligate intracellular organism, cellular rather than humoral responses could be involved. A comparison of amino acid sequences (GenBank®) reveals very similar homologies between P. gingivalis and C. pneumoniae GroEL with human HSP60 (around 50%). More important than sequence, however, would be determination of the cross-reactive epitopes of the proteins; clearly, further work is required in terms of mapping these.
Molecular mimicry may be one of several mechanisms that could occur in pathogen-induced atherosclerosis. A recent study showed up-regulation of innate immune markers, including Toll-like receptor 2 (TLR2) and TLR4, in aortic tissue soon after oral inoculation of apoE mice with P. gingivalis (Miyamoto et al., 2006). Ligation of TLR by products such as bacterial LPS, fimbriae, and both human and bacterial HSPs initiates signal transduction pathways, leading to enhanced innate inflammatory responses (reviewed in Gibson et al., 2006). TLR4 expression is enhanced by the presence of oxidized low-density lipoprotein (Xu et al., 2001), suggesting that inflammation due to pathogens may act synergistically with hypercholesterolemia to promote atherosclerosis. It has also been reported that direct bacterial invasion of the arterial wall could be a mechanism for atherosclerosis development, since wild-type P. gingivalis, but not a fimbriae-deficient mutant strain, up-regulated aortic TLR2 and TLR4 expression and accelerated atherosclerosis in apoE mice (Gibson et al., 2004).
We have shown that a high pathogen load of P. gingivalis resulted in a marked antibody response, including to GroEL, as well as increased atherosclerosis, compared with a lower pathogen load in this model. Treatment of periodontal disease, which is a means of lowering P. gingivalis load, has been shown to improve endothelial function in humans. albeit without documented cardiovascular disease (Mercanoglu et al., 2004). Establishment of a role for P. gingivalis in human atherosclerosis would provide a basis for targeting individuals with cardiovascular risk for mechanical periodontal treatment and possibly antibiotic therapy. Further mechanistic studies are urgently required.
| ACKNOWLEDGMENTS |
|---|
Received April 27, 2006; Last revision October 4, 2006; Accepted October 4, 2006
| REFERENCES |
|---|
|
|
|---|
Consensus report (1996) Periodontal diseases: pathogenesis and microbial factors. Ann Periodontol 1:926932.[Medline]
DeStefano F, Anda RF, Kahn S, Williamson DF, Russel CM (1993). Dental disease and the risk of coronary heart disease and mortality. BMJ 306:688691.[ISI][Medline]
Epstein SE (2002). The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 90:24.
Ford PJ, Gemmell E, Hamlet SM, Hasan A, Walker PJ, West MJ, et al. (2005). Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol 20:296302.[ISI][Medline]
Gemmell E, Winning TA, Grieco DA, Bird P, Seymour GJ (2000). The influence of genetic variation on the splenic T cell cytokine and specific serum antibody responses to Porphyromonas gingivalis in mice. J Periodontol 71:11301138.[ISI][Medline]
Gemmell E, Bird PS, Carter CL, Drysdale KE, Seymour GJ (2002a). Effect of Fusobacterium nucleatum on the T and B cell responses to Porphyromonas gingivalis in a mouse model. Clin Exp Immunol 128:238244.[ISI][Medline]
Gemmell E, Carter CL, Hart DN, Drysdale KE, Seymour GJ (2002b). Antigen-presenting cells in human periodontal disease tissues. Oral Microbiol Immunol 17:388393.[ISI][Medline]
Gemmell E, Bird PS, Ford PJ, Ashman RB, Gosling P, Hu Y, et al. (2004). Modulation of the antibody response by Porphyromonas gingivalis and Fusobacterium nucleatum in a mouse model. Oral Microbiol Immunol 19:247251.[ISI][Medline]
Gibson FC 3rd, Hong C, Chou HH, Yumoto H, Chen J, Lien E, et al. (2004). Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:28012806.
Gibson FC 3rd, Yumoto H, Takahashi Y, Chou HH, Genco CA (2006). Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis. J Dent Res 85:106121.
Grau AJ, Buggle F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, et al. (1997). Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 28:17241729.
Khader YS, Albashaireh ZS, Alomari MA (2004). Periodontal diseases and the risk of coronary heart and cerebrovascular diseases: a meta-analysis. J Periodontol 75:10461053.[ISI][Medline]
Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, et al. (2003). Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 23:14051411.
Li L, Messas E, Batista EL Jr, Levine RA, Amar S (2002). Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 105:861867.
Mercanoglu F, Oflaz H, Oz O, Gokbuget AY, Genchellac H, Sezer M, et al. (2004). Endothelial dysfunction in patients with chronic periodontitis and its improvement after initial periodontal therapy. J Periodontol 75:16941700.[ISI][Medline]
Miyamoto T, Yumoto H, Takahashi Y, Davey M, Gibson FC 3rd, Genco CA (2006). Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization. Infect Immun 74:13761380.
Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA (1987). Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231240.[ISI][Medline]
Polkinghorne A, Hogan RJ, Vaughan L, Summersgill JT, Timms P (2006). Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydoaphila pneumoniae infections. Microbes Infect 8:6172.[ISI][Medline]
Pussinen PJ, Jousilahti P, Alfthan G, Palosuo T, Asikainen S, Salomaa V (2003). Antibodies to periodontal pathogens are associated with coronary heart disease (comment). Arterioscler Thromb Vasc Biol 23:13091311; comment on Arterioscler Thromb Vasc Biol 23:12501254.
Snedecor GW, Cochran WG (1967). Statistical methods. 6th ed. Iowa: The Iowa State University Press.
Taniguchi A, Nishimura F, Murayama Y, Nagasaka S, Fukushima M, Sakai M, et al. (2003). Porphyromonas gingivalis infection is associated with carotid atherosclerosis in non-obese Japanese type 2 diabetic patients. Metabolism 52:142145.[ISI][Medline]
Valtonen VV (1999). Role of infections in atherosclerosis. Am Heart J 138:S431S433.[ISI][Medline]
Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. (2001). Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104:31033108.
Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H (1998). Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29:773778.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® |
| Journal of Dental Research ® | Critical Reviews (1990-2004) |